ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Colorectal Cancer

Colorectal Cancer

A set of genes that are more likely to be mutated in African-Americans vs Caucasians with colorectal cancer appears to increase the risk of metastases and relapse in mutant versions.

In this interview we discuss the GeneFx Colon test (or the ColDx assay), which can helpful identify patients with low- or high-risk stage II colon cancer.

A gene expression microarray-based assay was able to successfully identify patients with stage II colon cancer who are at high risk for recurrence.

A study found that fusobacteria, commonly found in the mouth, can enrich colorectal cancer cells, in a process mediated by the Fap2 protein.

Combination treatment with the MEK inhibitor cobimetinib and the anti–PD-L1 drug atezolizumab was active in patients with microsatellite-stable metastatic colorectal cancer.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

The USPSTF has issued an updated guideline with recommendations regarding screening for colorectal cancer. A systematic review found that screening can be of “substantial net benefit.”

Pages

Subscribe to Colorectal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.